PURPOSE: To evaluate the frequency and prognostic importance of neuroendocrine differentiation (NED) in Japanese breast cancer patients. METHODS: We used standard immunohistochemical techniques to examine 50 patients who underwent resection of breast cancer between 1988 and 1993 at the Department of Surgery II, Nagoya University Hospital, for NED, defined as positive reactivity for four markers: neuron-specific enolase (NSE), synaptophysin, CD57, and chromogranin A (CGA). Neuroendocrine differentiation was defined by the presence of at least one marker including CGA, CD57, and synaptophysin, or at least two markers when one was positive for NSE. RESULTS: Neuroendocrine differentiation was found in 13 (26%) of the 50 patients examined. There were no significant differences in the distribution of patients with positive or negative NED in terms of age, menopausal status, tumor size, lymph node metastasis, histological grade, ER, PgR, and HER2. We calculated the cumulative survival rates of patient groups according to NED status, and found no significant difference in overall or disease-free survival between patients with and those without NED. CONCLUSION: Neuroendocrine differentiation was identified in a subset (26%) of Japanese breast cancer patients, but this appeared to have no relationship with established prognostic factors or patient outcome.
PURPOSE: To evaluate the frequency and prognostic importance of neuroendocrine differentiation (NED) in Japanese breast cancerpatients. METHODS: We used standard immunohistochemical techniques to examine 50 patients who underwent resection of breast cancer between 1988 and 1993 at the Department of Surgery II, Nagoya University Hospital, for NED, defined as positive reactivity for four markers: neuron-specific enolase (NSE), synaptophysin, CD57, and chromogranin A (CGA). Neuroendocrine differentiation was defined by the presence of at least one marker including CGA, CD57, and synaptophysin, or at least two markers when one was positive for NSE. RESULTS: Neuroendocrine differentiation was found in 13 (26%) of the 50 patients examined. There were no significant differences in the distribution of patients with positive or negative NED in terms of age, menopausal status, tumor size, lymph node metastasis, histological grade, ER, PgR, and HER2. We calculated the cumulative survival rates of patient groups according to NED status, and found no significant difference in overall or disease-free survival between patients with and those without NED. CONCLUSION: Neuroendocrine differentiation was identified in a subset (26%) of Japanese breast cancerpatients, but this appeared to have no relationship with established prognostic factors or patient outcome.
Authors: T Kawasaki; S Nakamura; G Sakamoto; S Murata; H Tsunoda-Shimizu; K Suzuki; O Takahashi; T Nakazawa; T Kondo; R Katoh Journal: Histopathology Date: 2008-07-23 Impact factor: 5.087
Authors: A Miremadi; S E Pinder; A H S Lee; J A Bell; E C Paish; P Wencyk; C W Elston; R I Nicholson; R W Blamey; J F Robertson; I O Ellis Journal: Histopathology Date: 2002-03 Impact factor: 5.087
Authors: Maureen A Soh; Scott H Garrett; Seema Somji; Jane R Dunlevy; Xu Dong Zhou; Mary Ann Sens; Chandra S Bathula; Christina Allen; Donald A Sens Journal: Cancer Cell Int Date: 2011-11-18 Impact factor: 5.722
Authors: Esther Danenberg; Helen Bardwell; Vito R T Zanotelli; Elena Provenzano; Suet-Feung Chin; Oscar M Rueda; Andrew Green; Emad Rakha; Samuel Aparicio; Ian O Ellis; Bernd Bodenmiller; Carlos Caldas; H Raza Ali Journal: Nat Genet Date: 2022-04-18 Impact factor: 41.307